Hot chair

Northern Capsek Ventures

2025-10-21

Henrik Jerner, CEO of Northern CapSek Ventures AB, talks about the company’s ongoing process regarding a potential merger with portfolio company Arctic Space Technologies. Henrik also comments on the rights issue that starts today, October 21, and runs until November 4, focusing on how the net proceeds are intended to provide financial flexibility for the structural transaction, while also enabling selective add-on investments and increased ownership stakes in promising portfolio companies. Finally, he discusses key milestones and triggers, including CapSek’s paths forward regardless of whether the deal with Arctic Space Technologies is completed or not.

Transfer Group

2025-07-25

Mats Holmberg, CEO of Transfer Group AB (publ), discusses the Company’s ongoing divestment processes for the subsidiaries Sensec AB and Amigo Systems AB, as well as the strategy going forward for the remaining subsidiaries. Mats also provides an outlook on the valuation expected from the sale of Sensec and the potential for a shareholder dividend. Finally, the discussion touches upon the order intake in Transfer Group’s subsidiaries and the outlook for Altum Security AB and Safe AB.

Hoi Publishing

2025-03-28

Lars Rambe, CEO of Hoi Publishing, talks about the company's focus on film and television production, the potential of the acquisition of Eleven Stories and the launch of the new publishing imprint Lyrikhuset. The company has identified four film projects that have a good chance of reaching full financing during the year, which would make a clear contribution to both sales and profits already in 2025.

Brain+

2025-03-17

We have interviewed Kim Baden-Kristensen, CEO of Brain+. Kim shares insights into the company's operations, strategy, and future outlook. He also provides his perspective on the digital healthcare market and the key factors investors should keep an eye on in the coming years.

OncoZenge

2025-01-31

We have interviewed Stian Kildal, CEO of OncoZenge, who talks about the company's recent successes and investment agreement with Yangtian Pharma. The capital will be used to start the phase 3 study of BupiZenge™ and to strengthen OncoZenge's position in the global market.

Zwipe

2024-12-20

We have interviewed Robert Puskaric, CEO of Zwipe. Robert talks about the business, the ongoing rights issue and the strategy going forward. He also gives his view on the biometrics market and which potential value drivers investors should keep an eye on in 2025.

Goobit group

2024-12-04

We interviewed Rebecka Nakamato, mother of two, marathon runner and passionate bitcoiner. She talks about her journey from social scientist to her work at Goobit, where she organizes events, writes the BTCX newsletter and leads Les Femmes Orange. Rebecka also shares her insights into the power structures of money and why Bitcoin can create a more just economy.

DUG Foodtech

2024-10-28

Helene Nielsen, CEO of DUG Foodtech, talks about the company's products and the transformation that has taken place in the business. Helene also answers how the capital from the upcoming rights issue will be used, and what growth ambitions the company has.

Prebona

2024-10-18

In this interview, Christian Östberg, CEO of Prebona, talks about the company's focus on odor elimination and surface protection with their products OdorControl and DuraClean. With patented and environmentally friendly technology, they aim to become cash flow positive in Q1 2025 and expand in markets such as Germany, North America and Asia.

Kinda Brave

2024-10-17

Christian Kronegård, CEO of Kinda Brave, highlights the investment in the game HELA, which is fully funded through an agreement with Knights Peak. He also mentions the company's plans to expand into other media, such as TV and film, and to grow its portfolio of intellectual property rights.

Tangiamo Touch Technology

2024-10-16

In this interview, Christopher Steele, CEO at Tangiamo Touch Technology, shares insights on the acquisition of Trustplay and its significance for the company. He also emphasizes the ongoing rights issue's importance for growth and transformation.

Hoi Publishing

2024-09-24

In this interview, Lars Rambe, CEO of Hoi Publishing AB (publ), talks about the acquisition of a majority stake in Eleven Stories AB. Rambe also discusses the significance of the acquisition for the mobile media venture, as well as the significant revenue opportunities going forward.

OncoZenge

2024-09-10

Torben Mogensen, one of the co-inventors behind OncoZenge's drug candidate, BupiZenge™, shares insights into his background in anesthesiology and explains how the idea for BupiZenge™ was conceived. Additionally, Mogensen discusses the medical need for patients suffering from oral mucositis and shares his hopes for the future of BupiZenge™.

ZignSec

2024-08-16

Daniel Grech, CTO of ZignSec, discussed how he leverages his background in Computer Science and Statistics in the development of KYC and KYB solutions at ZignSec. Daniel outlines how ZignSec uses AI to automate compliance processes, ensuring both global scalability and adherence to regulatory requirements, while allowing experts to concentrate on high-risk cases. Daniel's approach is to enhance efficiency and ensure security in digital identification.

PExA

2024-07-09

Tomas Gustafsson, CEO of PExA AB (publ), describes how PExA is developing innovative instruments for non-invasive sampling of small airways in the lungs, which opens up new opportunities for research and diagnostics. The company sells and rents its instruments globally and is now conducting a 7.4 MSEK issue to strengthen marketing and participate in international congresses. PExA's market includes both research instruments and future diagnostics, with the potential to revolutionize the detection and treatment of lung diseases.

ZignSec

2024-06-06

Glenn Mac Donald, CEO of ZignSec, describes the Company's plan to use SEK 29 million from the latest rights issue to strengthen technology, marketing, and sales in Europe, Latin America, APAC, and Africa. The funds will also be used to hire senior salespeople and conduct targeted campaigns. ZignSec focuses on these regions due to their need for KYC and KYB solutions and distinguishes itself with a wide range of products that meet various customer demands, creating long-term customer loyalty and growth.

Carbiotix AB

2024-04-23

Erik Deaner, CEO of Carbiotix AB, discusses the company's work in microbiota research with its product Carbersol. By providing high-quality soluble fibers to the dietary supplement industry, Carbiotix aims to combat the global fiber shortage. The company strengthens its position through the NutraCycle service that converts waste products into valuable fibers, promoting a healthier diet and sustainable production.

PExA

2024-04-11

Tomas Gustafsson, CEO of PExA AB (publ), highlights the company's unique technology that is changing lung research. With an innovative instrument that enables the collection of samples from the small airways of the lungs, Tomas shows how PExA opens up new possibilities for early detection and treatment of lung diseases. The company's customer base encompasses the global research community and ranges from studies related to the work environment to research on lung cancer.

ZignSec

2024-03-01

In this interview, ZignSec CEO Glenn Mac Donald highlights the company's position as a leader in the RegTech sector, specializing in identity verification and compliance with KYC and AML guidelines. The business model is centered on providing efficient solutions for remote onboarding and due diligence. The company's future prospects are emphasized through a strategy focused on geographic expansion and investments in AI and LLM technologies to meet evolving market needs and drive growth.

Hoi Publishing

2024-02-16

Lars Rambe, CEO of Hoi Publishing, shares his story of the transition from corporate lawyer to author – a journey that gave him valuable insights into the publishing industry and led to the creation of Hoi, the first publicly listed publisher in the Nordic region. Hoi Publishing aims to expand its operations and reach a turnover of over SEK 200 million within five years, initially in the Nordic region and then globally. For 2024, the focus is on strengthening the synergies from its acquisitions, increasing turnover and generating profit.

Adverty

2024-02-16

Jonas Söderqvist, CEO of Adverty, talks about the company's unique technology that offers brands the opportunity to reach players in an engaging and seamless way. Jonas sees good growth prospects for Adverty, especially considering the ability to triple revenue annually and show profit at EBITDA and EBT levels. In 2024, the company is focused on increasing its growth within both advertisers and game publishers, as well as launching new products.

OncoZenge

2024-01-03

In this interview, Stian Kildal, CEO of OncoZenge, talks about the company's operations and their work on developing a lozenge for oral pain called "BupiZenge." During the interview, OncoZenge's strategies for getting the product to market, the collaboration with Ensysce Biosciences, the expansion into international markets, financial aspects and the goals for the company in 2024 are discussed.

Gabather

2023-12-13

In this interview with Gabather, CEO Michael-Robin Witt enlightens potential partnerships based on preliminary study results of their drug candidate GT-002, and the role of Big Pharma in the EEG/fMRI study design. Witt highlighted plans for GT-002, aiming for development and commercialization post-Phase 2 studies, and the significance of its potential EMA orphan drug classification. He concluded by outlining Gabather's main objectives for 2024. Witt also tells us more about the ongoing rights issue where they raise 28.6 MSEK.

Diagonal Bio AB

Karin Wehlin, interim CEO at Diagonal Bio, shares her extensive experience and talks about the company's progress, including commercialization of its CE-marked product and plans for 2024. She highlights challenges, emphasizes the company's attractive business model and market position.

ChargePanel AB

In this interview, Peter Persson, CEO of ChargePanel AB (publ), shares insights into various aspects of ChargePanel's operations and strategy. He describes the company's unique SaaS solution for charging infrastructure and highlights its independence from specific hardware, which positions them strongly in the market. Persson also touches on the revenue model based on subscriptions and roaming services, and their goal to achieve profitability by the end of 2024.

Diagonal Bio AB

In this interview with Diagonal Bio, the CEO Jack Egelund Madsen get further into Diagonals strategic choices for 2023. They've recently opted for a directed share issue and loan to strengthen the impact and focusing on the commercialization of LAMPlify™, recently CE-marked. Diagonal Bio aims to generate revenue and continue its innovative journey.

Scandinavian Real Heart

Ina Laura Perkins, CEO of Scandinavian Real Heart, talks about the groundbreaking technology behind the company's artificial heart, the results from the pre-clinical studies and how Real Heart plans to invest the funding from the current new share issue. Ina also shares the company's plans for the future.

Diagonal Bio AB

Jack Englund Madsen, CEO of Diagonal Bio AB tells us about the company's progress and about an external testing of Diagonal's patented technology made by an accredited laboratory. Jack also answers questions about Diagonal's two technologies - LAMPlify™ and PANVIRAL™.

Blick Global Group AB

Erik Ahlberg, CEO of Blick Global Group AB, talks about the company's strong Q4 results with 160% growth and higher profit margins. Erik shares the company's annual growth targets to be achieved through expansion, increased profitability and a continued clear pipeline for more acquisitions.

MeeW

Armin Kavousi, CEO at MeeW A/S, talks about the company's business model and how it has grown fast in a short time. MeeW is doing a new share issue in connection with an IPO and Armin thereby tells us how the issue proceeds will be used to internationalize MeeW.

Spermosens

Ulrik Nilsson, CEO of Spermosens AB (publ), talks about the product JUNO-Checked System, the company's current collaboration agreement and what the upcoming issue proceeds will be used for.

Plexian

Fredrik Knutsson, Vice President and Head of Commercialization at Plexian, talks about what the upcoming issue proceeds will be used for and about his area of responsibility for bringing the Edge platform to market.

Episurf Medical

Pål Ryfors, CEO of Episurf Medical, looks towards 2023 and has his sights set on the US market and the commercialization of Episealer.

BioArctic

Oskar Bosson, Investor Relations & Communications at BioArctic, talks about BioArctic's impressive progress, the partnership with Eisai and the great interest in the drug candidate Lecanemab.